Image de couverture de livre

Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT

Mantle cell lymphoma (MCL) predominantly affects older adults, and treatment options for relapsed/refractory (R/R) disease remain limited. Brexucabtagene autoleucel (brexu-cel) has demonstrated high efficacy in R/R MCL, but data in older adult populations are scarce. This retrospective, real-world a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Santoro, Nicole (Auteur) , Mooyaart, Jarl Edouard (Auteur) , Novak, Urban (Auteur) , Protheroe, Rachel (Auteur) , Ayuk, Francis (Auteur) , Dreger, Peter (Auteur) , van Meerten, Tom (Auteur) , Paneesha, Shankara (Auteur) , Sanderson, Robin (Auteur) , Ram, Ron (Auteur) , Northend, Michael (Auteur) , Forcade, Edouard (Auteur) , Huynh, Anne (Auteur) , Yakoub-Agha, Ibrahim (Auteur) , Hoogenboom, Jorinde Desiree (Auteur) , Coelho, Maiana Hamdan Melo (Auteur) , Pagliuca, Simona (Auteur) , Malard, Florent (Auteur) , Kuball, Jürgen (Auteur) , Sureda, Anna (Auteur) , Bazarbachi, Ali (Auteur) , Ruggeri, Annalisa (Auteur) , Rocha, Vanderson (Auteur)
Format: Article (Journal)
Langue:anglais
Publié: 12 May 2026
In: Blood advances
Year: 2026, Volume: 10, Numéro: 9, Pages: 3135-3142
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025019367
Accès en ligne:Verlag, kostenfrei, Volltext: https://doi.org/10.1182/bloodadvances.2025019367
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2473952926001928
Accéder au texte intégral
Notes sur l'auteur:Nicole Santoro, Jarl Edouard Mooyaart, Urban Novak, Rachel Protheroe, Francis Ayuk, Peter Dreger, Tom van Meerten, Shankara Paneesha, Robin Sanderson, Ron Ram, Michael Northend, Edouard Forcade, Anne Huynh, Ibrahim Yakoub-Agha, Jorinde Desiree Hoogenboom, Maiana Hamdan Melo Coelho, Simona Pagliuca, Florent Malard, Jürgen Kuball, Anna Sureda, Ali Bazarbachi, Annalisa Ruggeri, and Vanderson Rocha
Description
Résumé:Mantle cell lymphoma (MCL) predominantly affects older adults, and treatment options for relapsed/refractory (R/R) disease remain limited. Brexucabtagene autoleucel (brexu-cel) has demonstrated high efficacy in R/R MCL, but data in older adult populations are scarce. This retrospective, real-world analysis evaluated patients aged ≥70 years with R/R MCL treated with brexu-cel and reported to the EBMT registry between 2020 and 2024. A total of 233 patients from 96 centers across 13 countries were included (median age at infusion, 74.6 years; 44% >75 years). Most had Eastern Cooperative Oncology Group (ECOG) 0 to 1 (89%) and were heavily pretreated; 62% had prior Bruton tyrosine kinase inhibitor exposure. At day +100, the best overall response was complete remission in 78% and partial remission in 13%. At 30 days, the cumulative incidence of any-grade cytokine release syndrome was 80% (grade ≥3, 9%) and immune effector cell-associated neurotoxicity syndrome was 57% (grade ≥3, 22%). At 1 year, overall survival (OS) was 74%; progression-free survival (PFS), 62%; relapse/progression incidence, 25%; and nonrelapse mortality (NRM), 13%. Patients aged >75 years had outcomes comparable with those aged 70 to 75 years. In multivariable analysis, ECOG ≥2 remained the strongest predictor of inferior OS (hazard ratio [HR], 4.50; P < .001) and PFS (HR, 3.10; P < .001), whereas age was not independently associated with outcomes. Brexu-cel is effective in patients aged ≥70 years with R/R MCL, achieving high remission rates and meaningful survival, despite a relatively high incidence of NRM. Functional status, rather than age, should guide eligibility.
Description:Gesehen am 24.07.2026
Description matérielle:Online Resource
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025019367

Documents similaires